United States v. Fresenius Medical Care AG & Co. KGAAUnited States v. Fresenius Medical Care AG & Co. KGAA
ORDER ADOPTING REPORT AND RECOMMENDATION
COGAN, District Judge.
In this case under the False Claims Act (“FCA“), relator CKD Project, LLC, sued various entities connected to Fresenius Medical Care Holdings, Inc. (collectively, “defendants“), alleging that they maintained a “systematic and nationwide kickback scheme” in violation of the Anti-Kickback Statute (“AKS“),
Now before me are relator‘s objections. “A judge of the [district] court may accept, reject, or modify, in whole or in part, the findings or recommendations made by the magistrate judge.”
1. Relator first argues that the public disclosure bar does not apply to this case. The public disclosure bar provides that courts “shall dismiss an action or claim . . . if substantially the same allegations or transactions as alleged in the action or claim were publicly disclosed . . . unless . . . the person bringing the action is an original source of the information.” United States ex rel. Chorches for Bankr. Est. of Fabula v. Am. Med. Response, Inc., 865 F.3d 71, 79 (2d Cir. 2017) (quoting
At the first step, the R&R concluded that the substance of relator‘s claim had been disclosed in the 2013 Form 20-F that Fresenius Medical Care AG & Co. KGaA filed with the Securities and Exchange Commission. It provided:
If our joint ventures violate the law, our business could be adversely affected.
A number of the dialysis centers and vascular access centers we operate are owned, or managed, by joint ventures in which we hold a controlling interest and one or more hospitals, physicians or physician practice groups hold a minority interest. Physician owners, who are usually nephrologists, may also provide medical director services and physician owners may refer patients to those centers or other centers we own or operate or to other physicians who refer patients to those centers or other centers we own and operate. While we have structured our joint ventures to comply with many of the criteria for safe harbor protection under the U.S. Federal Anti-Kickback Statute, our investments in these joint venture arrangements do not satisfy all elements of such safe harbor. While we have established comprehensive compliance policies, procedures and programs to ensure ethical and compliant joint venture business operations, if one or more of our joint ventures were found to be in violation of the Anti-Kickback Statute or the Stark Law, we could be required to restructure or terminate them. We also could be required to repay to Medicare amounts received by the joint ventures pursuant to any prohibited referrals, and we could be subject to criminal and monetary penalties and exclusion from Medicare, Medicaid and other U.S. federal and state healthcare programs. Imposition of any of these penalties could have a material adverse effect on our business, financial condition and results of operations.
According to relator, this filing did not disclose the substance of its claims because it did not disclose facts that would satisfy each of the legal elements of an AKS claim. The SEC filing merely noted that the joint venture arrangement could violate
But this argument starts from a flawed premise. True, the public disclosure bar applies only if “substantially the same allegations or transactions as alleged in the action or claim were publicly disclosed,”
2. Next, relator argues that, even if the public disclosure bar would otherwise apply, relator falls within the exception for an “original source.” An “original source” is someone who “has knowledge that is independent of and materially adds to the publicly disclosed allegations or transactions, and who has voluntarily provided the information to the Government before filing an action.”
The problem, however, is that relator still offers little information on the source of its knowledge. Relator is not a whistleblower, but an entity formed solely for this litigation. It acquired its information from a third party, who the amended complaint described as “an inside participant in one of the fraudulent joint venture transactions” whose information was not “previously publicly disclosed within the meaning of
The objections do not shed any more light on this issue. Instead, relator argues that the R&R impermissibly drew an inference against relator by pointing out that some of the documents relator appended
3. Finally, relator argues that the R&R erred in recommending that leave to amend be denied. Although a court “should freely give leave when justice so requires,”
Relator‘s motion for leave to file a reply [81] is denied, the objections to the report and recommendation are overruled, and the report and recommendation [74] is adopted in full. The Clerk is directed to enter judgment, dismissing this case.
SO
Digitally signed by Brian M. Cogan
U.S.D.J.
Dated: Brooklyn, New York
July 30, 2021